NeuroSense Therapeutics Ltd. announced the results of a non-sponsored in vitro study of PrimeC in amyotrophic lateral sclerosis (ALS) conducted by Dr. Justin Ichida, PhD at the University of Southern California's (USC) Stem Cell Ichida Lab, part of the Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research at USC. Dr. Ichida'sin vitro study used induced pluripotent stem cells (iPSCs) that were derived from blood samples of people living with ALS. The survival rate of induced motor neurons when administered with PrimeC in comparison to each of PrimeC's components, ciprofloxacin and celecoxib, alone was evaluated.

PrimeC showed a significant beneficial effect relative to each of its components alone, demonstrating the synergistic effect of PrimeC and supporting the rationale of combining the two active components into NeuroSense's proprietary formulation. PrimeC attenuated ALS related pathology, as depicted by the increased survival rate. The PrimeC treated iPSCs had increased neuronal survival compared to ALS control cells, rendering their survival rate to be similar to healthy controls.

A previous study conducted independently by Dr. Ichida in iPSCs has already demonstrated NeuroSense's combination therapy performed among the best in improving motor neuron survival alongside several other ALS drugs in development and two FDA approved ALS drugs, Amylyx Pharmaceuticals' combination therapy, RELYVRIO, and Mitsubishi Tanabe's Radicava. Dr. Ichida is the John Douglas French Alzheimer's Foundation Associate Professor of Stem Cell Biology and Regenerative Medicine and a New York Stem Cell Foundation?Robertson Investigator. He is widely recognized as being on the cutting edge of future treatments and cures for ALS and Alzheimer's disease, as well as the use of iPSCs, a state-of-the art in vitro cellular technique, in drug testing and development.

Dr. Zimri will be presenting these results at the 22nd Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting which takes place October4-6, 2023 in Clearwater, Florida. NeuroSense expects clinical topline results from PARADIGM, its Phase 2b study of PrimeC in the treatment of ALS in the fourth quarter of 2023.